Skip to main content

You are here:

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

This study is being done to learn more about the effectiveness and safety of VX445/tezacaftor (TEZ)/ivacaftor (IVA) in patients with cystic fibrosis.

Key Eligibility Criteria

Diagnosis of Cystic fibrosis, Age 18yrs+

Therapeutic Area
Cystic Fibrosis
Type of Study
Clinical trial VX18-445-110
Study Status
Vertex Pharmaceuticals
Principal Investigator
Prof Edward McKone